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1  | INTRODUC TION
Cancer immunotherapy has become an emerging entity for cancer 
therapy. Cancer immunotherapy aims to trigger, enhance, or halt 
the negative regulators of the cancer- immunity cycle within the 
tumor microenvironment, which is postulated by Chen and Mellman 
(Figure 1).1 Examples include checkpoint blockers and adoptive 
transfer of engineered T lymphocytes expressing chimeric antigen 
receptors (CAR) that have shown outstanding outcomes in large- 
scale clinical trials and have benefited many patients with refractory 
cancers. Checkpoint blockers are a good example of an inhibitor of a 
negative regulator of the cancer- immunity cycle, whereas adoptive 
CAR- T cell therapy is considered to initiate and/or enhance the cycle. 
Significant effort has been made over the past decades to evaluate 
the therapeutic benefit of cancer immunotherapies. The next few 
years to come will see more immunotherapy products with cutting- 
edge technologies such as genome editing and induced pluripotent 
stem cell (iPSC) technologies in combination with other agents (ie, 
checkpoint blocker and CAR- T cells). Major challenges for cancer 
immunotherapy to broaden or generalize its applicability will be the 
evaluation of therapeutic benefits against a broader range of solid 
cancers, management of off- tumor and on- target toxicities, and re-
duction of prices. Checkpoint blockers have already shown active 
results in different types of solid cancers and more results from clin-
ical trials will follow. With respect to cost issues, researchers in the 
field of engineered T cell development have been considering alloge-
neic infusions instead of autologous cell manufacturing. In particular, 
the development of off- the- shelf engineered T- cell products that are 
inspired by cord- blood banks will not only reduce the cost of manu-
facturing, but serve as an ideal platform for synthetic T cells. In this 
review, we describe the current state of engineered T cell transfer 
with the focus on cell manufacturing processes and the potentials 
and challenges of iPSC- derived T cells as a starting material to con-
struct an off- the- shelf T cell bank.
2  | ENGINEERED T CELL S FOR C ANCER 
THER APY
Adoptive T cell transfer for cancer immunotherapy was initially 
demonstrated by the Rosenberg Laboratory in the NCI, USA, using 
T cells isolated from a patient's tumor on surgery, also known as 
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Recent outstanding clinical results produced by engineered T cells, including chi-
meric antigen receptors, have already facilitated further research that broadens their 
applicability. One such direction is to explore new T cell sources for allogeneic “off- 
the- shelf” adoptive immunotherapy. Human pluripotent stem cells could serve as an 
alternative cell source for this purpose due to their unique features of infinite propa-
gation ability and pluripotency. Here, we describe the current state of engineered T 
cell transfer with the focus on cell manufacturing processes and the potentials and 
challenges of induced pluripotent stem cell- derived T cells as a starting material to 
construct off- the- shelf T- cell banks.
K E Y W O R D S
antigen specificity, iPS cell, regenerative immunotherapy, T cell differentiation, T cell rejuvenation, 
     |  17IRIGUCHI and KanEKO
tumor- infiltrating lymphocytes (TILs). The isolated TILs are subse-
quently expanded ex vivo to obtain clinically relevant numbers for 
reinfusion.2 Since then, alternative approaches have been proposed 
and evaluated. Among them, Carl June's group at the University of 
Pennsylvania, USA, showed the feasibility of adoptive transfer of bulk 
T cells from peripheral blood (PBT) of patients expanded ex vivo in 
the presence of interleukin (IL)- 2.3 The first clinical trial using the ex-
panded PBT was implemented on patients with relapsed/refractory 
non- Hodgkin lymphoma following hematopoietic stem cell transfer 
and showed the safety of the procedure.4 These two seminal studies 
used a population of T cells with unknown antigen- specificity.
Researchers have also explored the potentials of tumor- antigen 
directed engineered T cells obtained from patient's blood.5,6 The 
manufacturing process involves isolation of PBT from patients and 
ex vivo expansion followed by retroviral transduction of a T- cell re-
ceptor (TCR) or CAR. For example, CAR T cells are generated from 
bulk PBMCs by aphaeresis, activated with CD3/28 beads, and trans-
duced with a viral vector harboring CAR. These production pro-
cesses take approximately 10- 14 days to obtain cell doses required 
for reinfusion. Importantly, the potential of engineered T cells has 
been well demonstrated in clinical trials obtained with NY- ESO- 1 
TCR7 and CD19 CAR.8-11 Last year, Novartis announced that the US 
FDA approved Kymriah (tisagenlecleucel), the first CAR- T therapy 
product, for B- cell precursor acute lymphoblastic leukemia. The 
price tag of Kymriah was determined to be $475 000 per patient, 
which astonished the community.
These initial encouraging results, as well as issues, call for fur-
ther research and development. For instance, current procedures do 
not clearly define the composition of T- cell subsets, which include 
CD4 helper and CD8 killer T cells. With regard to T- cell subsets, a 
recent preclinical study showed the synergistic antitumor activity 
of CD19 CAR- expressing CD4+ and CD8+ T cells, indicating that 
investigation of optimal composition might influence the therapeu-
tic efficacy.12 In addition, each T- cell subset also comprises naive, 
stem cell memory (Tscm), central memory (Tcm), effector memory 
(Tem), and terminal effector cells with distinct in vivo persistence 
and effector functions (Figure 2).13,14 Several groups already eval-
uated the potential of T- cell subsets in preclinical models and hu-
mans and found that T cells with more immature phenotypes, such 
as Tcm cells, sustain longer in vivo with presumably better antitu-
mor effects.15-18 In line with these findings, significant effort has 
been made to optimize ex vivo culture methods that promote self- 
renewal of Tcm. It appeared that inclusion of IL- 15 together with 
IL- 2 during ex vivo culture favors self- renewal of CD8+ Tcm cells.18
Although the therapeutic benefits of engineered T cells are 
now apparent, several issues remain to be solved.19 Clearly, cost 
of the products needs to be reduced in order to make it econom-
ically practical. One approach under evaluation is allogeneic ther-
apy. Autologous T cell therapy will remain in the frontline of target 
validation and the production cost will be reduced with upcoming 
new technologies. Once the efficacy of a target is validated, then the 
development of banked T- cell source that is immediately ready upon 
the need would contribute to broaden the applicability and cost re-
duction of adoptive T cell therapies. Figure 3 shows a schema of 3 
different forms of engineered T cell infusions. However, the major 
challenges for allogeneic adoptive T cell transfer include striking the 
F IGURE  1 Cancer- immunity cycle. The 
induction of antitumor immunity is a cyclic 
process that can be self- propagating. It 
can amplify and extend T cell responses 
against cancer cells. It also contains 
several inhibitory factors itself to halt the 
cycle when the target cells (cancer cells) 
are eradicated. The cycle can be divided 
into 7 steps, as illustrated, starting with 
the release of cancer antigens from the 
cancer cells and ending with the killing of 
cancer cells. APC, antigen- presenting cell; 
DC, dendritic cell. (Adapted from Chen 
and Mellman,1 with permission.)
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balance between rejection response from the host immunity and al-
loresponse to the host by infusing T cells. In particular, alloreactivity 
of donor T cells increases the risk of off- tumor tissue destruction, 
also known as graft- vs- host disease (GvHD). Therefore, safety as-
sessments would be crucial when implementing allogeneic T cell 
therapy. Other important issue includes poor progression- free sur-
vival for ALL patients treated with CD19- CART cells.20
3  | CELL SOURCE FOR ALLOGENEIC T 
CELL IMMUNOTHER APY
The current candidates of cell sources for allogeneic T cell thera-
pies can be divided into 2 categories: peripheral blood T cells from 
healthy donors and iPSC- derived T cells. Both candidates are being 
actively investigated within academia and industry. With respect 
to donor PBT approaches, Cellectis (Paris, France) already started 
a phase I clinical trial last year using CD19- directed CAR- T cells in 
patients with refractory B- cell acute lymphoblastic leukemia and so 
far demonstrated the feasibility of the approach. Cellectis exploits 
a unique approach for allogeneic CAR- T cell manufacturing in that 
they disrupt the constant region of the α- chain of the TCR gene 
(TRAC) by a gene editing technology, expecting to reduce the risk 
of GvHD. In addition, they also incorporated disruption of the CD52 
gene to provide the cells with the resistance to Alemtuzumab treat-
ment during preconditioning. The other strategy to manage the risk 
of GvHD is the selection of virus- specific TCRs devoid of alloreactiv-
ity, although unpredictable cross- reactivity would be a concern.21 
Compared to the development of healthy donor PBT approaches, 
iPSC- derived T cells are still in the preclinical stage of development. 
As iPSC- derived somatic cells themselves are still under safety as-
sessment in a clinical trial, functional assessment of iPSC- derived T 
cells will require a few more years. For future clinical trials and sub-
sequent commercialization to come, it is critical to establish cGMP- 
compatible manufacturing process development, which includes the 
generation of iPSCs, differentiation of iPSCs to T cells, and expansion 
of iPSC- derived T cells (Figure 3). Successful process development 
would require comprehensive knowledge and experts of molecular 
biology, developmental biology, stem cell biology, immunology, and 
regulatory sciences. For the rest of this review, we will summarize 
the current status of human PSC- derived T cell research.
4  | PLURIPOTENT STEM CELL S A S TRUE 
“OFF- THE- SHELF” T CELL S IN THE ER A OF 
SYNTHETIC BIOLOGY
Since reported in 1998, human ESCs have been expected to become 
an ultimate cell source for regenerative medicine due to the features 
of pluripotency; they can be propagated indefinitely while maintain-
ing the ability to differentiate into all types of somatic cells in vitro. 
Within a decade from the first report of human ESC establishment, 
Shinya Yamanaka of Kyoto University (Kyoto, Japan) reported the 
successful reprogramming of mouse and later human somatic cells 
into pluripotency by transducing 4 transcription factors essential to 
ESCs.22,23 The reprogrammed cells are termed iPSCs. Because iPSCs 
can be derived from a variety of somatic cells, including adult skin fi-
broblasts and blood cells, it is considered that iPSC technology leads 
to tailor- made regenerative medicine and hence the use of other-
wise harmful immunosuppressive drugs, required for allogeneic 
transplantation, can be avoided. These features have accelerated 
the research and development of regenerative medicine using PSCs.
To date, several investigators, including our laboratory, have 
reported the feasibility of generating T cells from human ESCs and 
iPSCs. The first evidence showing in vitro differentiation of T cells 
from ESCs was reported by Timmermans et al.24 They utilized a well- 
established hematopoietic differentiation protocol using OP9 feeder 
layers from ESCs and a T cell differentiation protocol established for 
human hematopoietic stem cells.25,26 The resulting cells expressed 
markers characteristic to T cells, such as CD3, and TCR and ex-
panded and secreted γ- interferon and tumor necrosis factor follow-
ing TCR stimulation. Later in 2013, 3 groups from Japan reported 
the generation and redifferentiation of iPSCs from antigen- specific 
T cells.27-29 In a series of papers, we and others have reported the 
regeneration of T cells from a T- cell clone by reprogramming it into 
iPSCs and by redifferentiation into CD8+ T cells. The regenerated 
T cells maintained the same TCR genomic sequence to the original 
T cell clone. The redifferentiated T cells not only maintained the 
same antigen specificity, but they showed longer telomere length 
F IGURE  2 Antitumor activity and T cell subsets. After an 
antigen exposure, naïve T cells (Tn) vigorously expand and 
differentiate to central memory T cells (Tcm) and progressively 
become effector T cells (Te) with higher cytotoxic ability. Although 
Te shows the maximum cytotoxic ability within the mature T- cell 
subsets, it is short- lived and the cells readily undergo apoptosis. It is 
believed that Tcm or Tscm cells are the ideal T- cell subset for T- cell 
cancer immunotherapy due to its higher in vivo persistence when 
compared to Tem, Te, and Tex cells. Tem, T effector memory; Tex, 
exhausted T cell. (Part of this figure is adapted from Gattinoni et 
al,14 with permission.)
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compared to the original T cell clones, indicating that the rediffer-
entiated T cells had rejuvenated through the reprograming process. 
The proliferative ability of redifferentiated T cells was remarkably 
higher than those of the original T cell clone. This technique allows 
us to generate a large number of rejuvenated T cell clones. In addi-
tion, the feasibility of generation of CAR- T cells from iPSCs has been 
reported.30 Collectively, these studies showed the proof- of- concept 
that T cells with antigen- specific activities could be generated from 
pluripotent stem cells by TCRs and CARs.
Although the aforementioned studies show the potential of iPSC- 
derived T cells as an alternative cell source for T cell immunotherapy, 
recent studies, including those at our laboratory, revealed that T cells 
differentiated from iPSCs using the current differentiation methods 
display features similar to γδT cells or innate lymphoid cells.30-32 
Current differentiation culture induces T cells expressing CD56, a 
marker for natural killer cells, during multiple rounds of expansion. 
Another deviation from normal thymocyte development observed 
during PSC differentiation is earlier expression of TCRs at the CD4−/
CD8− stage when iPSCs derived from T cells (T- iPSCs) are used. It 
could be possible that prerearranged TCRs in T- iPSCs and their ear-
lier expression during culture skewed the differentiating cells toward 
innate- like lymphocytes. Alternatively, T cells induced from fetal- like 
F IGURE  3 Schema of induced pluripotent stem (iPS)- based allogeneic T- cell immunotherapy. 1. General schema illustrating autologous 
T cell manufacturing. Autologous T cell manufacturing starts with patient selection followed by apheresis blood collection at a certified 
facility. Blood sample is shipped to a cell processing center, where the T cells are activated, selected for CD3, and subsequently transduced 
with a viral vector harboring a chimeric antigen receptor or a T- cell receptor. The expanded cells are washed and cryopreserved for quality 
control (QC) release tests. Products are then shipped to an infusion center and infused to the patient. 2. Proposed schema of allogeneic T 
cell manufacturing. For this strategy, healthy donors for banking are selected and used to produce a cell bank after transduction with viral 
vector before patient selection. This leads to off- the- shelf allogeneic T- cell immunotherapy. 3. Perspective schema of allogeneic iPSC- 
derived T cell infusion. In this approach, master cell banks are first established after thorough QC and safety tests. Thereafter, a working 
cell bank is generated for multiple (10- 1000) doses. Following patient identification, a vial is shipped to an infusion center and the product 
is immediately infused into the patient. Circles in red indicate potential points of manufacturing failure. Examples of failure points for 
autologous infusion include failure to obtain a sufficient number of PBMCs from the patient at apheresis, unsuccessful expansion after T cell 
activation and/or gene transduction efficiency, and health condition of the patient at the infusion. On the contrary, allogeneic infusions of 
healthy donor PBT and iPSC- T manufacturing could fail if the product cannot pass QC tests at the construction of a working cell bank (eg, 
too many dead cells or low gene transduction efficiency to meet the specifications). The major challenge for iPSC- derived T cell infusion 
would be how to generate master cell banks (whether it is at the iPSC stage or intermediate product (s) during differentiation). (Part of this 
figure is modified from Clarke et al.49)
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hematopoietic stem and progenitor cells (HSPCs), which are thought 
to be a counterpart of iPSC- derived HSPCs, render these properties 
as suggested in previous studies. These results call for further ad-
vancement and refinement of the current differentiation protocols.
Generation of T cells from PSCs requires comprehensive under-
standing of developmental biology and immunology to recapitulate 
the key events that occur during T cell commitment.33 The key events 
are illustrated in Figure 4. The initial event is the induction of me-
soderm, which is followed by hemogenic endothelial cell derivation. 
The next key step is called endothelial- to- hematopoietic transition, 
the mechanism through which heterogeneous populations of HSPCs 
are generated.34 The other milestone is to induce T cell commitment 
of HSPCs. The final step represents maturation of CD4+/CD8β+ 
double- positive cells into CD4 or CD8 single- positive (SP) cells.35 A 
challenge in the field is to develop a chemically defined differenti-
ation culture, as most reports use several uncharacterized compo-
nents in the cultures that include FBS and xenogeneic feeder layers 
(ie, OP9 and OP9/DL1 feeder cells). For this purpose, Kennedy et al 
developed a feeder- and serum- free embryoid body- based hemato-
poietic differentiation method and identified a population with ro-
bust T cell potential.36 Of note, the authors showed that inhibition of 
a SMAD pathway during the mesoderm induction selectively induced 
hemogenic endothelial cells with T cell potential. The study showed 
the possibility that manipulation of developmental cues during cul-
ture influence the outcome of later stages (ie, HSPCs and T cells). 
On the contrary, differentiation of T cells from iPSC- derived HSPCs 
under feeder- and serum- free conditions has not been reported de-
spite the fact that such culture conditions for bone marrow or cord 
blood HSPCs are available. Attempts to develop defined conditions 
for T cell differentiation will require further investigations, but once 
succeeded, it will also provide novel insights into human thymocyte 
differentiation as well as hematopoietic development, which is oth-
erwise impossible to study. The other challenge for this field is to 
define the condition to selectively induce CD8SP and CD4SP T cells, 
although a recent report showed the feasibility of making both sub-
sets by means of organoid culture from HSPCs.37
F IGURE  4 Key steps for differentiation of T cells from hematopoietic pluripotent stem cells (hPSCs). To make T cells from induced 
PSCs requires multiple key steps. The steps can be divided into 3 stages: 1. hematopoietic induction; 2. T cell differentiation; and 3. T 
cell maturation. Each stage can be subdivided into several steps. To induce hematopoietic differentiation, PSCs are first are induced to 
differentiate into the mesodermal cells and further instructed to hemogenic endothelium. Hemogenic endothelium cells then undergo a 
process known as endothelial- to- hematopoietic transition (EHT) where they round up in morphology and gain expression of hematopoietic 
markers, such as CD43 and CD45. Newly formed hematopoietic stem and progenitors (HSPCs) with lymphoid differentiation potential are 
further directed to T cell commitment in the presence of NOTCH signaling and become pre T cells expressing CD7, which then become CD4 
expressing immature single- positive (ISP) cells. ISPs subsequently acquire the expression of CD8β and become CD4+ and CD8αβ+ double- 
positive (DP) cells, now holding a T cell receptor on the surface. Finally, DP cells mature into either CD4+ CD8− or CD4– CD8+ single- 
positive (SP) T cells. HPC, hematopoietic progenitor cell; RTE, recent thymic emigrant
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5  | PERSPEC TIVE
In this article, we have gone through the initial success of T cell immuno-
therapy for cancer with the focus on the development of CD19- CART 
cell therapy, and explored the potential and challenges of iPSC- derived 
T cells as an alternative cell source for allogeneic T cell immunotherapy. 
The in vivo safety and antitumor activities of iPSC- derived T cells rela-
tive to primary T cells should be carefully and thoroughly examined 
in patients after undertaking in- depth in vivo functional and safety 
assessments in preclinical models, such as xenograft models or non- 
human primate models. Further investigation of mechanisms that 
underlie the differentiation of T cells from PSCs is warranted to gain 
more precise control to generate T cells with functions comparable to 
primary T cells. In parallel, efforts to scale up cell manufacturing pro-
cesses and deal with regulatory requirements must not be overlooked.
Although we described the properties of iPSC T cells, other con-
siderations need to be made when undertaking allogeneic therapy. 
One of them is to circumvent the risk of rejection, given that long- 
term persistence correlates to therapeutic efficacy by CD19- CART 
therapy. Accumulating evidence from allogeneic renal and bone mar-
row transplantations suggests that matching HLA- A, - B, and - DR are 
beneficial to graft survival, indicating that HLA matching would be 
preferred in allogeneic iPSC- T cell therapy.38-42 Accordingly, banking 
of iPSCs generated from common HLA- homozygous donors has been 
proposed and is currently under development at the Center for iPS 
Research and Application (CiRA), Kyoto University.43 In CiRA, it has 
been estimated that an iPSC bank with 50 unique HLA- homozygous 
iPSC lines would cover approximately 73% of the Japanese popula-
tion, assuming matching at HLA- A, - B, and - DRB1 loci.44 Similarly, 
another study also estimated generating 150 selected HLA homozy-
gous lines would match 93% of the UK population.45 To date, CiRA 
has already accomplished the development and delivery of the first 
HLA- homozygous iPSC, which will match to approximately 17% of 
the Japanese population and several clinical studies are underway or 
under planning using the iPSC grafts. For allogeneic iPSC- T cell ther-
apy, HLA- homozygous iPSCs transduced with either CAR or TCR will 
be used as a starting material to construct an iPSC- T cell bank. Other 
strategy actively considered is generation of “the universal donor” 
iPSC by disrupting HLA genes. In addition to HLA deletion, a recent 
report showed that overexpression of HLA- E in HLA- deficient iPSCs 
reduced natural killer cell- mediated rejection, which is augmented 
when HLA genes are disrupted.46
The other critical issue that is worth mentioning is how we 
manage the risk of alloreactivity of infusing T cells. Alloreactivity 
would be a particular concern to allogeneic T cell therapy as it may 
attack and destroy host tissues. Therefore, the choice of TCRs will 
be critical to overall therapeutic benefits to patients. One approach 
to this problem would be to use Epstein-Barr virus- reactive TCRs. 
Alternatively, deletion of TCRs by the means of genome editing 
could minimize the alloreactivity, as reported by a recent study.47
Finally, once clinical potentials are evaluated, iPSC- derived T 
cell technology could become the best platform to undertake gene 
manipulations to enhance functions or even add desired functions. 
For example, a recent study showed a proof of concept that overex-
pression of IL- 7 and CCL19 in CAR, designated as 7 × 19 CAR- T cells, 
significantly enhanced in vivo antitumor functions.48 Significantly, 
depletion of host T cells prior to 7 × 19 CAR- T cells reduced antitu-
mor activity, indicating that injection of 7 × 19 CAR- T cells acceler-
ated the cancer- immunity cycle. Combining these new technologies 
with iPSC- derived T cells will generate a novel synthetic T cell. 
Autologous T cell therapy will remain the frontrunner to logically 
evaluate candidate targets. Once the therapeutic efficacy of the 
target is validated, allogeneic T cells derived from PSCs could play 
a role in the future.
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